PDS Biotechnology Presents Results Of National Cancer Institute-Led Study Of Investigational Interleukin-12 Tumor Targeted Immunocytokine, PDS01ADC, At AACR Special Conference

NCI-Led Study Shows Median PFS of 9.6 Months 

Results Presented at AACR Special Conference on Innovations in Prostate Cancer

PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that results of a National Cancer Institute ("NCI")-led study of the Company's investigational Interleukin-12 (IL-12) tumor targeted immunocytokine, PDS01ADC, were presented at the American Association of Cancer Research ("AACR") special conference on prostate cancer research, held in Boston, MA on January 20-22, 2026.

The study, titled Docetaxel and the Tumor-Targeting Interleukin-12 ("IL-12") PDS01ADC in Patients with Metastatic Castration-Resistant Prostate Cancer ("mCRPC"), was presented by Melissa Abel, MD., Assistant Research Physician, Genitourinary Malignancies Branch, Center for Cancer Research, at the NCI, part of the National Institutes of Health ("NIH"). The clinical study is being done to evaluate the ability of PDS01ADC to enhance responses to docetaxel in advanced prostate cancer, based on the potential synergy of PDS01ADC with the necrosis inducing chemotherapeutic agent. The study was performed in advanced cancer patients, the majority of whom had failed 2nd line treatment with androgen deprivation therapy and an androgen pathway inhibitor (ARPI), and therefore had few remaining treatment options (3rd line). Results showed median progression-free survival ("PFS") of 9.6 months (range: 4.3–32.2 months) for the combination therapy in mCRPC patients. Additionally, a promising median PSA decline of 40% was observed, with 6 of 16 patients achieving greater than 50% decline.